Randomized Placebo Controlled Trial To Assess Role Of Low Dose Aspirin In Venous Ulceration

New randomized placebo controlled trial studies role of low dose aspirin as adjuvant in venous ulcers and concludes that it may not improve healing of leg ulcers.

Can Aspirin Therapy Benefit Patients With Peripheral Vascular Disease?
Peripheral vascular disease patients may not benefit from aspirin therapy, finds a recent study from the University of Florida.

‘Low dose aspirin (≤ 150 mg) may not be useful in increasing healing of venous ulcers in the leg, when used in addition to standard compression treatment’

Highlights:

Current study was undertaken to confirm whether adjuvant low dose aspirin (≤ 150 mg) (with fewer side effects and better safety profile) would be effective in the healing of venous ulcers
Two earlier trials have suggested that 300 mg aspirin may be beneficial as adjuvant treatment to compression therapy in chronic venous ulceration of the leg.

This randomized, double blind, placebo controlled trial undertaken in New Zealand, to evaluate the adjuvant effect of low dose aspirin in healing of venous ulcers, concludes that it may not particularly improve healing of venous ulceration of the leg when used with compression stockings or bandages, which remains the mainstay in the treatment of chronic venous insufficiency.

Screening for Vascular Disease Saves One Life for Every 169 Patients Assessed (VIVA)
National screening programmes are implemented for different types of cancer, yet there is limited research on similar programmes for asymptomatic cardiovascular disease.

Role Of Low Dose Aspirin In Venous Ulcer Healing – Methods Of The Study

The current study was undertaken following earlier trials that suggested a beneficial role of 300 mg aspirin in the healing of venous leg ulcers The study employed low dose aspirin (≤ 150 mg) which is safer to use in elderly patients (with fewer adverse effects such as bleeding)

Participants included 251 patients receiving community care nursing services from five study centers throughout New Zealand (Auckland, Dunedin, Christchurch South Auckland and Waikato).
As it was a double blind study, neither the participants nor the persons conducting the trial (the research team) knew who was getting a particular treatment. This was done to reduce bias which could otherwise affect the results.
125 participants were randomized to low dose aspirin and 126 were randomized to the placebo.
The participants received either 150 mg or less oral aspirin or a matching placebo for a period of 24 weeks, while continuing on standard compression treatment for venous ulcers in the background.
Recruitment for the trial began on 1st March 2015 and was due to be completed on 30th September 2016, however was extended to 23rd December 2016.
The main outcome measured was the time taken for complete healing of the reference ulcer (largest ulcer if more than one ulcer was present). Secondary results evaluated included proportion of participants healed, change in ulcer size, impact on general health and quality of life, and adverse events.

Aspirin Therapy Can Fight Pregnancy Loss Due to High Blood Pressure
Evidence supports the use of low-dose Aspirin to counter the effects of High Blood Pressure during pregnancy.

Role Of Low Dose Aspirin In Venous Ulcer Healing - Results Of The Study

The median number of days taken for healing of the reference ulcer was 77 days in the aspirin group and 69 in the placebo group.
The number of participants whose ulcers had healed at the endpoint was 101 (80%) in the placebo group and 88 (70%) among the aspirin group.
Estimated change in ulcer size was 4.8 cm2 in the placebo group and 4.1 cm2 in those who received aspirin.
40 adverse reactions were seen among 29 participants in the aspirin group and 37 adverse events among 27 participants who had received placebo.
Two hundred and thirty two (92.4%) participants filled the quality of life questionnaires given at start and end point of the trial. No statistically significant changes were reported.

Based on the findings of this study, the authors conclude that low dose aspirin has no benefit when used with compression therapy in the healing of leg ulcers.

Genetic Variations in Individuals Alters Effect of Aspirin, NSAIDs on Colon Cancer
Scientists have found that genetic variations of drugs like aspirin, non-steroidal anti-inflammatory drugs can reduce its impact on treating colorectal cancer.

Possible Mechanism Of Action Of Aspirin In Healing Of Venous Ulcers

Aspirin (a platelet inhibiting agent) has been advocated as a potential treatment option in venous ulcers due to the following reasons.

Persons with venous ulcers have increased platelet activation and aggregation activity seen.
Persons with chronic venous insufficiency have been found to have higher platelet counts and platelet reactivity in comparison with normal controls.

Thus the platelet inhibiting role is thought to have a potentially beneficial role in the healing of chronic venous ulcers of the leg. It has been shown that platelet inhibition can be achieved by aspirin doses as low as 81 mg although there may obviously be individual variations in the response.

Comparison Of Current Study Versus Two Earlier Trials

Two previous smaller trials with a total of 71 participants using 300 mg aspirin have suggested that aspirin at this dose may be beneficial but a Cochrane review failed to find sufficient evidence to support the claim.

There is no trial evidence to support the role of low dose aspirin (150 mg) when used as an adjuvant with compression therapy to improve the healing of venous ulcers.

Conclusion

The contradictory results between the earlier trials and the present study might be due to the dose of aspirin or bias in the earlier trials. However, the results of newer trials using 300 mg aspirin are still awaited and until then aspirin should not be used as adjuvant in the treatment of venous ulceration in the leg.
Source-Medindia